Recently, the efficacy of the anti-IP-10 antibody MDX-1100 reported in a phase 2 clinical trial for RA [44] reinforced the crucial role of the CXCL10-CXCR3 axis in this disease, and the therapeutic potential of small molecule CXCR3 antagonists [45]. Here, CXCR3 is linked to rheumatoid arthritis.